Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603054 | 1.00 | GSR (0.53) | GSRGNAI3GNAO1GNAI1CPB2 | |
| Hydrochloric Acid SCHEMBL28125330 | 0.98 | GSR (0.52) | GSRGNAI3GNAO1GNAI1CPB2 | |
| Hydrochloric Acid SCHEMBL28125331 | 0.98 | GSR (0.52) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL8778639 | 0.94 | GSR (0.45) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL8778638 | 0.94 | GSR (0.45) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL1003010 | 0.89 | GSR (0.53) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL22494143 | 0.87 | GSR (0.52) | GSRGNAI3GNAO1GNAI1CPB2 | |
| Hydrochloric Acid SCHEMBL21802388 | 0.87 | GSR (0.52) | GSRGNAI3GNAO1GNAI1CPB2 | |
| Hydrochloric Acid SCHEMBL6704964 | 0.87 | GSR (0.52) | GSRGNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL23457451 | 0.84 | GSR (0.57) | GSRGNAI3GNAO1GNAI1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104603145-B | β-hairpin peptidomimetics | 波利弗尔股份公司 | 2018-05-18 | — | — | CN | claimed |
| CN-104603145-A | Beta-hairpin peptidomimetics | POLYPHOR AG | 2015-05-06 | — | — | CN | claimed |
| CN-103703018-A | Beta-hairpin peptidomimetics as CXC4 antagonists | POLYPHOR AG | 2014-04-02 | — | — | CN | claimed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2023235929-A1 | FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USES THEREOF | NOXOPHARM LIMITED (AU) | 2023-12-14 | — | — | WO | disclosed |
| EP-4282867-A1 | INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| EP-3668867-B1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIV REGENSBURG (DE) | 2023-10-04 | — | — | EP | disclosed |
| CN-115073327-B | Method for preparing glutarimide by using urea as carbonylation agent | 中国科学院过程工程研究所 | 2023-05-30 | — | — | CN | disclosed |
| CN-115073327-A | Method for preparing pentanedicarbamate by using urea as carbonylation agent | 中国科学院过程工程研究所 | 2022-09-20 | — | — | CN | disclosed |
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | UNIVERSITÄT REGENSBURG (DE) | 2022-07-12 | — | — | US | disclosed |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | disclosed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| US-4163034-A | DECYCLIZATION, ESTERIFICATION; FIREPROOFING | HOECHST AG. (DE) | 1979-07-31 | — | — | US | disclosed |
| US-4096208-A | FIREPROOFING AGENTS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384076-B2 | Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors | FLT3, CSF3R, ABL1 | GSR 2905/4885GNAI3 992/4885GNAO1 2191/4885 |
| US-20200190075-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | FLT3, CSF3R, ABL1 | GSR 2905/4885GNAI3 992/4885GNAO1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.